New combo therapy aims to control advanced colorectal cancer
NCT ID NCT07391618
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new first-line treatment for people with advanced colorectal cancer that cannot be removed by surgery or has spread. The treatment combines two drugs, levozolinate and 5-FU, given together through an IV. The goal is to see if this approach helps control the cancer longer and with fewer side effects. About 583 participants will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chinese PLA General Hospital, Beijing
RECRUITINGBeijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo shrink Hard-to-Treat colorectal tumors?
- New drug combo aims to outperform standard therapy for advanced colorectal cancer
- New cocktail of drugs aims to tackle tough colorectal cancer
- Cottonseed compound plus immunotherapy takes on tough colorectal cancer
- New drug cocktail hopes to tackle advanced colon cancer
- New targeted combo aims to outsmart Hard-to-Treat colorectal cancer